DAG Mimicry and EBC-46: How Tigilanol Tiglate Activates Protein Kinase C to Disrupt Tumour Biology

Tigilanol tiglate (EBC-46) mimics diacylglycerol to activate protein kinase C, triggering a cascade of vascular disruption and tumour necrosis. Here's the mechanistic science behind this pathway.

Marcus Webb

14 Apr 2026 — 3 min read

Among the molecular mechanisms that make EBC-46 (tigilanol tiglate) a subject of significant research interest, its ability to mimic diacylglycerol (DAG) stands out as particularly elegant. This DAG mimicry is the foundational event in the cascade that leads to protein kinase C (PKC) activation and, ultimately, to the vascular disruption and tumour necrosis observed in published studies.

Diacylglycerol: The Natural PKC Switch

Protein kinase C is a family of enzymes that regulate many fundamental cellular processes — proliferation, differentiation, survival, and death. Under normal conditions, PKC isoforms exist in an inactive state in the cytoplasm. Their activation requires two co-signals: calcium ions (Ca²⁺) and diacylglycerol, a lipid second messenger produced when phospholipase C cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) in response to receptor activation.

DAG binds to the C1 domain of PKC, inducing a conformational change that translocates the enzyme to the plasma membrane — where it becomes active. This is a tightly regulated signalling event under normal physiological circumstances, ensuring PKC activation occurs only in appropriate cellular contexts.

How EBC-46 Mimics DAG

Tigilanol tiglate is a member of the tigliane-type diterpene ester family. Its molecular architecture closely resembles DAG at the structural level, allowing it to bind to C1 domains of PKC isoforms — particularly the novel and conventional PKC isoforms that include C1 domains. Published research, including work by QBiotics Group and associated academic collaborators, demonstrates that EBC-46 binds to PKC with high affinity and drives sustained activation rather than the transient activation seen with endogenous DAG.

This sustained activation is mechanistically important. While physiological DAG is rapidly metabolised, tigilanol tiglate persists at the C1 binding site, producing prolonged PKC signalling. In tumour tissue, this sustained PKC activation triggers a set of downstream events that disrupt the tumour microenvironment.

Downstream: From PKC Activation to Vascular Disruption

PKC-delta, one of the isoforms activated by tigilanol tiglate, plays a particularly prominent role in the observed anti-tumour effects. PKC-delta activation induces apoptosis in endothelial cells — the cells lining tumour blood vessels. Loss of endothelial cell integrity disrupts the tumour vasculature, cutting off the nutrient and oxygen supply that tumours depend on.

Simultaneously, PKC activation drives the release of pro-inflammatory cytokines and activates innate immune components within the tumour microenvironment. The combined effect — vascular collapse, immune activation, and direct cytotoxic effects on tumour cells — produces the rapid haemorrhagic necrosis that has been documented in both animal models and early human trials.

Selectivity and the Intratumoural Injection Model

In published pharmaceutical studies, tigilanol tiglate has been administered as a direct intratumoural injection (as in the Stelfonta veterinary product). This delivery approach is critical to understanding the mechanism's selectivity: by concentrating EBC-46 within the tumour mass, the PKC activation and subsequent vascular disruption occur primarily within the tumour boundaries rather than systemically.

For oral supplement consumers, it is important to understand that the research base on DAG mimicry and PKC activation in published studies reflects pharmaceutical-grade intratumoural administration. Oral blushwood berry extract supplements contain tigilanol tiglate as one of many seed constituents and are classified as dietary supplements, not pharmaceutical preparations. The full pharmacodynamic implications of oral bioavailability of tigilanol tiglate in seed extract form remain an area of ongoing scientific interest.

Broader PKC Biology and Research Implications

The PKC family includes at least 12 isoforms with distinct tissue distribution and signalling roles. The selectivity with which tigilanol tiglate activates specific PKC isoforms — and the downstream consequences of that selectivity — continues to be characterised in the scientific literature. Research published through institutions including PubMed/NCBI documents the mechanistic basis of tigilanol tiglate's activity in preclinical models, providing the molecular framework that informs ongoing clinical investigation.

Understanding DAG mimicry also helps explain why tigilanol tiglate has been of interest across multiple cancer histologies — PKC signalling pathways are broadly relevant across tumour types, though sensitivity and response vary by isoform expression profile and tumour microenvironment characteristics.

How EBC-46 Disrupts Tumour Vasculature: The PKC-Delta to Endothelial-Damage Cascade

Calcium-Dependent PKC Activation by EBC-46: Why the C1 Domain Matters